Skip to content


  • Oral presentation
  • Open Access

Estimating the number of HTLV-2 infected persons in the world

Retrovirology201512 (Suppl 1) :O5

  • Published:


  • General Population
  • Blood Donor
  • Prevalence Estimate
  • Population Data
  • Vertical Transmission

The number of HTLV-1 infected persons in the world has recently been estimated to be at least at 5 to 10 million or perhaps higher due to unavailable data (Gessain and Cassar Front Microbiol 2012). We decided to undertake a similar estimation for HTLV-2 infection. A targeted review of the literature revealed HTLV-2 prevalence estimates in blood donors (as a surrogate for the general population) and specific recognized high prevalence subpopulations in different regions of the world. Because blood donors are selected for low risk of viral infection and good health, we multiplied their prevalence by a factor of five to estimate the population prevalence. Data from studies using sensitive and specific assays for HTLV-2 antibody were preferred. Population data were obtained from national censuses or, for certain high-risk groups, Google searches. For each subpopulation, prevalence was multiplied by the size of the population. We estimate that there are 800,000 (range 670,000 - 890,000) HTLV-2 infected persons globally. The largest number of such persons is in the United States (400,000-500,000) reflecting the confluence of endemic Amerindian, hyperendemic injection drug user (IDU) and secondary sexual spread to the general population. Brazil had the second-largest population of infected persons at 200,000-250,000 and a similar epidemiology. In Europe, where HTLV-2 infection is found almost exclusively among IDU, we estimate about 20,000-40,000 persons. Although they have the highest prevalence, other endemic Amerindian and Pygmy populations in Latin America and central Africa have very small populations and therefore contribute no more than 50,000-100,000 infected persons globally. In conclusion, the burden of HTLV-2 infection in the world is about 6 to 12 fold lower than that of HTLV-1. This represents a concentration of infection in specific high-risk groups and a lower degree of sexual and vertical transmission within the general population than for HTLV-1.

Authors’ Affiliations

Departments of Laboratory Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, California, USA
Blood Systems Research Institute, San Francisco, California, USA
Département de Virologie, Institut Pasteur, Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Paris, France
UMR 3569, Centre National de la Recherche Scientifique, Paris, France


© Murphy et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.